Which has stronger earnings & valuation, TALK or INFU?

Talkspace has higher revenue and earnings than InfuSystem. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Talkspace $228.87M 3.84 $7.79M N/A N/A InfuSystem $143.34M 1.72 $870K $0.41 29.78

Is TALK or INFU more profitable?

InfuSystem has a net margin of 1.12% compared to Talkspace's net margin of 0.08%. InfuSystem's return on equity of 2.78% beat Talkspace's return on equity. Company Net Margins Return on Equity Return on Assets Talkspace 0.08% 0.17% 0.14% InfuSystem 1.12% 2.78% 1.41%

Does the media prefer TALK or INFU?

In the previous week, Talkspace had 5 more articles in the media than InfuSystem. MarketBeat recorded 8 mentions for Talkspace and 3 mentions for InfuSystem. InfuSystem's average media sentiment score of 1.73 beat Talkspace's score of 0.24 indicating that InfuSystem is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Talkspace 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InfuSystem 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to GMRS or INFU?

In the previous week, InfuSystem had 1 more articles in the media than GMR Solutions. MarketBeat recorded 3 mentions for InfuSystem and 2 mentions for GMR Solutions. InfuSystem's average media sentiment score of 1.73 beat GMR Solutions' score of 1.16 indicating that InfuSystem is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GMR Solutions 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InfuSystem 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer FLGT or INFU?

In the previous week, InfuSystem had 1 more articles in the media than Fulgent Genetics. MarketBeat recorded 3 mentions for InfuSystem and 2 mentions for Fulgent Genetics. InfuSystem's average media sentiment score of 1.73 beat Fulgent Genetics' score of 1.30 indicating that InfuSystem is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InfuSystem 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

InfuSystem (INFU) Competitors

$12.21 +0.01 (+0.08%)

As of 08/21/2026 04:00 PM Eastern

Compare

INFU vs. TALK, GMRS, FLGT, SRTA, and TOI

Should you buy InfuSystem stock or one of its competitors? InfuSystem's main competitors and comparable companies include Talkspace (TALK), GMR Solutions (GMRS), Fulgent Genetics (FLGT), Strata Critical Medical (SRTA), and Oncology Institute (TOI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does InfuSystem compare to Talkspace?

Talkspace (NASDAQ:TALK) and InfuSystem (NYSE:INFU) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Talkspace has higher revenue and earnings than InfuSystem.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talkspace	$228.87M	3.84	$7.79M	N/A	N/A
InfuSystem	$143.34M	1.72	$870K	$0.41	29.78

Talkspace currently has a consensus target price of $5.56, suggesting a potential upside of 5.95%. InfuSystem has a consensus target price of $16.67, suggesting a potential upside of 36.50%. Given InfuSystem's stronger consensus rating and higher possible upside, analysts plainly believe InfuSystem is more favorable than Talkspace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talkspace	1 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

57.4% of Talkspace shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 23.5% of Talkspace shares are owned by company insiders. Comparatively, 10.8% of InfuSystem shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Talkspace has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market. Comparatively, InfuSystem has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market.

In the previous week, Talkspace had 5 more articles in the media than InfuSystem. MarketBeat recorded 8 mentions for Talkspace and 3 mentions for InfuSystem. InfuSystem's average media sentiment score of 1.73 beat Talkspace's score of 0.24 indicating that InfuSystem is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Talkspace	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InfuSystem	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

InfuSystem has a net margin of 1.12% compared to Talkspace's net margin of 0.08%. InfuSystem's return on equity of 2.78% beat Talkspace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talkspace	0.08%	0.17%	0.14%
InfuSystem	1.12%	2.78%	1.41%

Summary

InfuSystem beats Talkspace on 9 of the 14 factors compared between the two stocks.

How does InfuSystem compare to GMR Solutions?

GMR Solutions (NYSE:GMRS) and InfuSystem (NYSE:INFU) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

GMR Solutions presently has a consensus target price of $18.67, indicating a potential upside of 37.56%. InfuSystem has a consensus target price of $16.67, indicating a potential upside of 36.50%. Given GMR Solutions' higher possible upside, research analysts clearly believe GMR Solutions is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GMR Solutions	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

71.1% of InfuSystem shares are owned by institutional investors. 10.8% of InfuSystem shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

InfuSystem has higher revenue and earnings than GMR Solutions. GMR Solutions is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GMR Solutions	N/A	N/A	N/A	-$1.56	N/A
InfuSystem	$143.34M	1.72	$870K	$0.41	29.78

In the previous week, InfuSystem had 1 more articles in the media than GMR Solutions. MarketBeat recorded 3 mentions for InfuSystem and 2 mentions for GMR Solutions. InfuSystem's average media sentiment score of 1.73 beat GMR Solutions' score of 1.16 indicating that InfuSystem is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GMR Solutions	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InfuSystem	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

InfuSystem has a net margin of 1.12% compared to GMR Solutions' net margin of 0.00%. InfuSystem's return on equity of 2.78% beat GMR Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GMR Solutions	N/A	N/A	N/A
InfuSystem	1.12%	2.78%	1.41%

Summary

InfuSystem beats GMR Solutions on 11 of the 14 factors compared between the two stocks.

How does InfuSystem compare to Fulgent Genetics?

Fulgent Genetics (NASDAQ:FLGT) and InfuSystem (NYSE:INFU) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

48.1% of Fulgent Genetics shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 36.2% of Fulgent Genetics shares are owned by insiders. Comparatively, 10.8% of InfuSystem shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, InfuSystem had 1 more articles in the media than Fulgent Genetics. MarketBeat recorded 3 mentions for InfuSystem and 2 mentions for Fulgent Genetics. InfuSystem's average media sentiment score of 1.73 beat Fulgent Genetics' score of 1.30 indicating that InfuSystem is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InfuSystem	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

InfuSystem has a net margin of 1.12% compared to Fulgent Genetics' net margin of -26.05%. InfuSystem's return on equity of 2.78% beat Fulgent Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-26.05%	-4.93%	-4.50%
InfuSystem	1.12%	2.78%	1.41%

InfuSystem has lower revenue, but higher earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.70	-$60.51M	-$2.82	N/A
InfuSystem	$143.34M	1.72	$870K	$0.41	29.78

Fulgent Genetics has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, InfuSystem has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market.

Fulgent Genetics presently has a consensus target price of $27.50, suggesting a potential upside of 38.19%. InfuSystem has a consensus target price of $16.67, suggesting a potential upside of 36.50%. Given Fulgent Genetics' higher possible upside, research analysts plainly believe Fulgent Genetics is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

InfuSystem beats Fulgent Genetics on 13 of the 16 factors compared between the two stocks.

How does InfuSystem compare to Strata Critical Medical?

Strata Critical Medical (NASDAQ:SRTA) and InfuSystem (NYSE:INFU) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Strata Critical Medical currently has a consensus price target of $8.00, suggesting a potential upside of 28.21%. InfuSystem has a consensus price target of $16.67, suggesting a potential upside of 36.50%. Given InfuSystem's higher possible upside, analysts plainly believe InfuSystem is more favorable than Strata Critical Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Strata Critical Medical	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Strata Critical Medical has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market. Comparatively, InfuSystem has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market.

In the previous week, InfuSystem had 3 more articles in the media than Strata Critical Medical. MarketBeat recorded 3 mentions for InfuSystem and 0 mentions for Strata Critical Medical. InfuSystem's average media sentiment score of 1.73 beat Strata Critical Medical's score of 0.00 indicating that InfuSystem is being referred to more favorably in the news media.

Company	Overall Sentiment
Strata Critical Medical	Neutral
InfuSystem	Very Positive

Strata Critical Medical has a net margin of 15.71% compared to InfuSystem's net margin of 1.12%. InfuSystem's return on equity of 2.78% beat Strata Critical Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Strata Critical Medical	15.71%	-2.97%	-2.54%
InfuSystem	1.12%	2.78%	1.41%

47.4% of Strata Critical Medical shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 15.5% of Strata Critical Medical shares are held by company insiders. Comparatively, 10.8% of InfuSystem shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Strata Critical Medical has higher revenue and earnings than InfuSystem. Strata Critical Medical is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Strata Critical Medical	$197.14M	2.80	$41.35M	-$0.04	N/A
InfuSystem	$143.34M	1.72	$870K	$0.41	29.78

Summary

InfuSystem beats Strata Critical Medical on 9 of the 16 factors compared between the two stocks.

How does InfuSystem compare to Oncology Institute?

InfuSystem (NYSE:INFU) and Oncology Institute (NASDAQ:TOI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

InfuSystem has a net margin of 1.12% compared to Oncology Institute's net margin of -7.42%. InfuSystem's return on equity of 2.78% beat Oncology Institute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
Oncology Institute	-7.42%	N/A	-24.68%

InfuSystem has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market. Comparatively, Oncology Institute has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

71.1% of InfuSystem shares are held by institutional investors. Comparatively, 36.9% of Oncology Institute shares are held by institutional investors. 10.8% of InfuSystem shares are held by company insiders. Comparatively, 4.4% of Oncology Institute shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

InfuSystem currently has a consensus target price of $16.67, suggesting a potential upside of 36.50%. Oncology Institute has a consensus target price of $8.50, suggesting a potential upside of 63.90%. Given Oncology Institute's higher probable upside, analysts plainly believe Oncology Institute is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

InfuSystem has higher earnings, but lower revenue than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$143.34M	1.72	$870K	$0.41	29.78
Oncology Institute	$545.76M	0.94	-$60.61M	-$0.37	N/A

In the previous week, InfuSystem had 3 more articles in the media than Oncology Institute. MarketBeat recorded 3 mentions for InfuSystem and 0 mentions for Oncology Institute. InfuSystem's average media sentiment score of 1.73 beat Oncology Institute's score of 0.00 indicating that InfuSystem is being referred to more favorably in the media.

Company	Overall Sentiment
InfuSystem	Very Positive
Oncology Institute	Neutral

Summary

InfuSystem beats Oncology Institute on 13 of the 16 factors compared between the two stocks.

Get InfuSystem News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INFU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INFU vs. The Competition

Export

Metric	InfuSystem	Healthcare Providers & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$246.42M	$9.83B	$7.37B	$24.30B
Dividend Yield	N/A	2.55%	2.53%	3.70%
P/E Ratio	203.53	34.38	272.88	30.31
Price / Sales	1.72	4.97	618.96	19.89
Price / Cash	12.79	125.12	78.62	32.49
Price / Book	4.94	4.05	13.05	6.77
Net Income	$870K	$311.06M	$3.47B	$1.07B
7 Day Performance	-0.49%	0.83%	2.09%	-0.65%
1 Month Performance	37.35%	2.42%	6.64%	3.38%
1 Year Performance	27.59%	15.69%	25.02%	14.90%

InfuSystem Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INFU InfuSystem	4.1801 of 5 stars	$12.21 +0.1%	$16.67 +36.5%	+27.6%	$246.42M	$143.34M	203.53	410	Positive News
TALK Talkspace	1.9807 of 5 stars	$5.24 flat	$5.56 +6.2%	N/A	$877.77M	$245.73M	N/A	500
GMRS GMR Solutions	4.7612 of 5 stars	$12.03 -4.9%	$19.22 +59.8%	N/A	$683.25M	$5.83B	42.96	N/A	News Coverage Positive News Analyst Forecast
FLGT Fulgent Genetics	3.6401 of 5 stars	$19.00 -0.3%	$27.50 +44.7%	-8.6%	$524.44M	$322.67M	N/A	1,315	Positive News
SRTA Strata Critical Medical	1.8077 of 5 stars	$6.03 +1.5%	$8.00 +32.7%	N/A	$513.97M	$197.14M	N/A	130

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:INFU) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InfuSystem (INFU) Competitors

INFU vs. TALK, GMRS, FLGT, SRTA, and TOI

How does InfuSystem compare to Talkspace?

Summary

How does InfuSystem compare to GMR Solutions?

Summary

How does InfuSystem compare to Fulgent Genetics?

Summary

How does InfuSystem compare to Strata Critical Medical?

Summary

How does InfuSystem compare to Oncology Institute?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INFU vs. The Competition

InfuSystem Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InfuSystem (INFU) Competitors

INFU vs. TALK, GMRS, FLGT, SRTA, and TOI

How does InfuSystem compare to Talkspace?

Which has stronger earnings & valuation, TALK or INFU?

Do analysts recommend TALK or INFU?

Do insiders & institutionals hold more shares of TALK or INFU?

Which has more risk & volatility, TALK or INFU?

Does the media prefer TALK or INFU?

Is TALK or INFU more profitable?

Summary

How does InfuSystem compare to GMR Solutions?

Do analysts recommend GMRS or INFU?

Do insiders and institutionals believe in GMRS or INFU?

Which has better earnings & valuation, GMRS or INFU?

Does the media refer more to GMRS or INFU?

Is GMRS or INFU more profitable?

Summary

How does InfuSystem compare to Fulgent Genetics?

Do institutionals and insiders hold more shares of FLGT or INFU?

Does the media prefer FLGT or INFU?

Is FLGT or INFU more profitable?

Which has higher valuation & earnings, FLGT or INFU?

Which has more risk and volatility, FLGT or INFU?

Do analysts rate FLGT or INFU?

Summary

How does InfuSystem compare to Strata Critical Medical?

Do analysts prefer SRTA or INFU?

Which has more risk and volatility, SRTA or INFU?

Does the media refer more to SRTA or INFU?

Is SRTA or INFU more profitable?

Do institutionals & insiders have more ownership in SRTA or INFU?

Which has higher earnings & valuation, SRTA or INFU?

Summary

How does InfuSystem compare to Oncology Institute?

Is INFU or TOI more profitable?

Which has more volatility and risk, INFU or TOI?

Do insiders & institutionals hold more shares of INFU or TOI?

Do analysts prefer INFU or TOI?

Which has better earnings and valuation, INFU or TOI?

Does the media favor INFU or TOI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INFU vs. The Competition

InfuSystem Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools